Improvement In Health-Related Quality of Life After Treatment with Resmetirom in Cirrhotic and Non-Cirrhotic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Data From MAESTRO‑NAFLD
Zobair M Younossi, MD, MPH, FAASLD
, Abstract Presenter
MASLD
6:15 PM
- 6:30 PM
Apr
29
2026
Washington, D.C.
Relationship of Diurnal Eating Behaviors and Incident MASLD and Cirrhosis in a Pooled Analysis of Three Large Prospective Cohorts
Robert M Wilechansky, MD
, Abstract Presenter
MASLD
Objectives
Analyze findings from large real-world data sets to identify trends, gaps, and implications for patient management and future research.
Describe the natural history and progression patterns of MASH, including risk factors for fibrosis advancement and liver-related outcomes